RU2017134418A3 - - Google Patents

Download PDF

Info

Publication number
RU2017134418A3
RU2017134418A3 RU2017134418A RU2017134418A RU2017134418A3 RU 2017134418 A3 RU2017134418 A3 RU 2017134418A3 RU 2017134418 A RU2017134418 A RU 2017134418A RU 2017134418 A RU2017134418 A RU 2017134418A RU 2017134418 A3 RU2017134418 A3 RU 2017134418A3
Authority
RU
Russia
Application number
RU2017134418A
Other languages
Russian (ru)
Other versions
RU2017134418A (ru
RU2762685C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017134418A publication Critical patent/RU2017134418A/ru
Publication of RU2017134418A3 publication Critical patent/RU2017134418A3/ru
Application granted granted Critical
Publication of RU2762685C2 publication Critical patent/RU2762685C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2017134418A 2011-07-12 2012-07-12 Выявление аффинно-зрелых человеческих антител RU2762685C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161506749P 2011-07-12 2011-07-12
US61/506,749 2011-07-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2014102617A Division RU2636045C2 (ru) 2011-07-12 2012-07-12 Выявление аффинно-зрелых человеческих антител

Publications (3)

Publication Number Publication Date
RU2017134418A RU2017134418A (ru) 2019-02-07
RU2017134418A3 true RU2017134418A3 (enExample) 2021-06-10
RU2762685C2 RU2762685C2 (ru) 2021-12-22

Family

ID=47506915

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2014102617A RU2636045C2 (ru) 2011-07-12 2012-07-12 Выявление аффинно-зрелых человеческих антител
RU2017134418A RU2762685C2 (ru) 2011-07-12 2012-07-12 Выявление аффинно-зрелых человеческих антител

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2014102617A RU2636045C2 (ru) 2011-07-12 2012-07-12 Выявление аффинно-зрелых человеческих антител

Country Status (11)

Country Link
US (6) US9234030B2 (enExample)
EP (2) EP3034513B1 (enExample)
JP (1) JP6731702B2 (enExample)
KR (1) KR102139388B1 (enExample)
CN (2) CN107090459A (enExample)
AU (2) AU2012281078B2 (enExample)
CA (1) CA2841475C (enExample)
IL (2) IL230358B (enExample)
MX (2) MX361600B (enExample)
RU (2) RU2636045C2 (enExample)
WO (1) WO2013009967A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841475C (en) * 2011-07-12 2021-02-09 Xbiotech Inc. Identifying affinity-matured human antibodies
WO2014144495A1 (en) 2013-03-15 2014-09-18 Abvitro, Inc. Single cell bar-coding for antibody discovery
GB201316644D0 (en) * 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
US10533204B2 (en) 2014-05-30 2020-01-14 National University Corporatlon University of Toyama Method for amplifying a T cell receptor (TCR) cDNA
MX394895B (es) 2014-06-03 2025-03-24 Xbiotech Inc Composiciones útiles para el tratamiento de infecciones por staphylococcus aureus.
US10590483B2 (en) 2014-09-15 2020-03-17 Abvitro Llc High-throughput nucleotide library sequencing
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
US12703882B2 (en) * 2019-06-14 2026-08-11 The Regents Of The University Of California Methods of sequencing antibody chains from hybridomas and kits for practicing same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068682A1 (en) 2000-03-10 2001-09-20 Large Scale Biology Corporation Self antigen vaccines for treating b cell lymphomas and other cancers
AU2002953381A0 (en) * 2002-12-18 2003-01-09 Diatech Pty Ltd In vivo affinity maturation scheme
WO2005017529A1 (en) * 2003-07-29 2005-02-24 Genentech, Inc. Assay for human anti cd20 antibodies and uses therefor
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
JP5205597B2 (ja) * 2007-06-01 2013-06-05 静岡県 1細胞レベルでの抗体遺伝子の解析・同定方法
RU2011117213A (ru) * 2008-09-30 2012-11-10 Эббот Лэборетриз (Us) Улучшенные библиотеки антител
CA2751669C (en) * 2009-02-20 2017-11-21 F. Hoffmann-La Roche Ag Method for obtaining immunoglobulin encoding nucleic acid
CA2841475C (en) * 2011-07-12 2021-02-09 Xbiotech Inc. Identifying affinity-matured human antibodies

Also Published As

Publication number Publication date
US9234030B2 (en) 2016-01-12
EP2731965A2 (en) 2014-05-21
EP2731965A4 (en) 2015-06-03
CN103687873A (zh) 2014-03-26
RU2636045C2 (ru) 2017-11-17
US20160362679A1 (en) 2016-12-15
US9453217B2 (en) 2016-09-27
EP3034513A3 (en) 2016-08-10
US20170233457A1 (en) 2017-08-17
US20200071388A1 (en) 2020-03-05
RU2017134418A (ru) 2019-02-07
AU2012281078A1 (en) 2014-01-23
US20130018173A1 (en) 2013-01-17
IL230358B (en) 2018-11-29
JP2014521316A (ja) 2014-08-28
US20160060618A1 (en) 2016-03-03
US9394536B2 (en) 2016-07-19
WO2013009967A2 (en) 2013-01-17
IL262977A (en) 2018-12-31
WO2013009967A3 (en) 2013-04-04
EP3034513B1 (en) 2020-09-02
US20160060619A1 (en) 2016-03-03
CA2841475C (en) 2021-02-09
KR102139388B1 (ko) 2020-07-30
RU2014102617A (ru) 2015-08-20
AU2017210585B2 (en) 2019-07-25
MX2018015450A (es) 2021-11-16
CA2841475A1 (en) 2013-01-17
CN103687873B (zh) 2016-10-19
RU2762685C2 (ru) 2021-12-22
KR20140044905A (ko) 2014-04-15
EP3034513A2 (en) 2016-06-22
AU2017210585A1 (en) 2017-08-24
MX361600B (es) 2018-12-11
CN107090459A (zh) 2017-08-25
JP6731702B2 (ja) 2020-07-29
IL262977B (en) 2020-07-30
US9670483B2 (en) 2017-06-06
MX2014000431A (es) 2014-09-04
AU2012281078B2 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
BR112013022641A2 (enExample)
BR112013031251A2 (enExample)
BR112013027245A2 (enExample)
BR112013024383A2 (enExample)
BR112013026905A2 (enExample)
BR112013023185A2 (enExample)
BR112013022995A2 (enExample)
BR112013017670A2 (enExample)
BR112013026744A2 (enExample)
AP3853A (enExample)
BR112013023927A2 (enExample)
BR112013027452A2 (enExample)
BR112013024365A2 (enExample)
BR112013028733A2 (enExample)
BR112013027121A2 (enExample)
AP2016009466A0 (enExample)
BR112013026790A2 (enExample)
BR112013024588A2 (enExample)
BR112013031556A2 (enExample)
BR112013032368A2 (enExample)
BR112013018949A2 (enExample)
BR112013032377A2 (enExample)
BR112013026895A2 (enExample)
BR112013027761A2 (enExample)
BR112013021637A2 (enExample)